Factorial Partners LLC lowered its position in Perrigo Company plc (NYSE:PRGO – Free Report) by 61.5% in the third quarter, HoldingsChannel reports. The firm owned 20,000 shares of the company’s stock after selling 32,000 shares during the period. Factorial Partners LLC’s holdings in Perrigo were worth $525,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Venturi Wealth Management LLC acquired a new position in Perrigo in the third quarter valued at about $56,000. Beach Investment Counsel Inc. PA acquired a new position in shares of Perrigo in the 2nd quarter worth approximately $72,000. KBC Group NV boosted its position in shares of Perrigo by 25.1% during the 3rd quarter. KBC Group NV now owns 4,517 shares of the company’s stock worth $118,000 after purchasing an additional 905 shares during the period. Voisard Asset Management Group Inc. raised its position in Perrigo by 520.0% in the second quarter. Voisard Asset Management Group Inc. now owns 4,650 shares of the company’s stock valued at $119,000 after purchasing an additional 3,900 shares during the period. Finally, Atria Investments Inc acquired a new position in Perrigo during the third quarter worth $208,000. Institutional investors and hedge funds own 95.91% of the company’s stock.
Insiders Place Their Bets
In other news, Director Katherine C. Doyle sold 8,954 shares of Perrigo stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $27.30, for a total transaction of $244,444.20. Following the completion of the sale, the director now directly owns 6,009 shares in the company, valued at approximately $164,045.70. This trade represents a 59.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Ronald Craig Janish sold 13,000 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $29.40, for a total value of $382,200.00. Following the completion of the sale, the executive vice president now directly owns 20,553 shares in the company, valued at $604,258.20. This trade represents a 38.74 % decrease in their position. The disclosure for this sale can be found here. 0.40% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on PRGO
Perrigo Stock Performance
Shares of PRGO opened at $27.24 on Wednesday. The company’s 50 day simple moving average is $25.97 and its 200-day simple moving average is $27.17. Perrigo Company plc has a 12-month low of $23.89 and a 12-month high of $34.60. The firm has a market cap of $3.72 billion, a PE ratio of -23.28 and a beta of 0.48. The company has a current ratio of 2.56, a quick ratio of 1.77 and a debt-to-equity ratio of 0.94.
Perrigo (NYSE:PRGO – Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.81 EPS for the quarter, meeting analysts’ consensus estimates of $0.81. Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the business posted $0.64 earnings per share. Perrigo’s quarterly revenue was down 3.2% on a year-over-year basis. As a group, equities analysts predict that Perrigo Company plc will post 2.56 EPS for the current year.
Perrigo Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 17th. Shareholders of record on Friday, November 29th will be paid a $0.276 dividend. The ex-dividend date is Friday, November 29th. This represents a $1.10 annualized dividend and a yield of 4.05%. Perrigo’s dividend payout ratio is currently -94.02%.
Perrigo Company Profile
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Featured Stories
- Five stocks we like better than Perrigo
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Dutch Bros’ Growth Perks: Can This Coffee Stock Hit New Highs?
- Investing In Preferred Stock vs. Common Stock
- Rocking the Charts: Why Live Nation Could Hit New Highs
- Do ETFs Pay Dividends? What You Need to Know
- Don’t Miss a Second Chance to Buy These 2024 Winners for 2025
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company plc (NYSE:PRGO – Free Report).
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.